Sisters in Sorrow and Durga’s Incarnations: the double-edged sword of shakti

This article examines the relationship between the depiction of women and femininity in Hindu myth and the lives and possible oppression of Hindu women today. The author synthesizes this question with Sallie McFague\u27s theory that the way in which cultures use language to construct god(s) reveals how that culture conceptualizes the roles of different members of the community. The first notion that Pyle pursues within this question is dharma. Dharma can be roughly understood as the fulfillment of each person\u27s appropriate role. For women, their primary dharma is to care for their husband and their children. This often consists of a level of nurturing and obedience that places all of their needs and concerns below the needs and concerns of their spouses and children. This idea is embodied in the story of Sita, which women have often told as a way of commiserating on the challenges of womanhood. This story, however, found a retelling in the hands of Mahatma Gandhi, who emphasized Sita\u27s independence and strength in order to bring women into the political arena. Sita\u27s perfectly obedient femininity is juxtaposed, however, with Durga, the warrior goddess who reigns over kings and warriors and who defeats demons no god could. Both of these figures are in possession of Shakti: the force that gives and destroys life. Pyle asks how two such images can exist within one understanding of Hindu womanhood. She concludes that they cannot: that the two forms exist simultaneously, both as perfect representations of femininity. Through the lens of Sallie McFague, Pyle concludes that Hindu woman have the right to decide when they feel oppressed, and at that point to use their own voice and language to redefine womanhood when it becomes necessar

Claiming a Space of Empowerment: Exploring Hispanic Feminist Theology and the Struggle towards Justice and Liberation

Pyle links liberation and empowerment to the carving out of space. Those individuals and communities who live without space, who have borders incessantly drawn around them, preventing them from building their own space, are those who suffer oppression most deeply. Hispanic women profoundly experience this spacelessness. Finding a remedy for this requires that they build a community in a space they make for themselves. Pyle looks towards the Lady of Guadalupe as a potential example and inspiration to these women. While disappointed by the current representation of this image as ultimately submissive, the author challenges Hispanic women to claim this woman as their own, recraft her image, and create a space of empowerment based around this newly understood symbol. Their community in religion can lead to the destruction of the boundaries which limit them and the creation of a new, liberated community

Re-mapping Tacoma\u27s Pre-War Japantown: Living on the Tideflats

This article, drawing on oral histories with Nisei, addresses the dearth of publications about pre-WWII Japanese life in the urban U.S. and provides evidence of Japanese immigrants’ active presence in the lumber industry and on Tacoma’s tideflats. This is important not only for Tacoma’s history and a fuller accounting of the major industries that shaped the south Puget Sound region, but also because Japanese contributions to early industrial development are often overlooked. The oral history narratives also stretch the boundaries of what has been depicted as a densely-connected and lively Japanese community in the downtown core. Also, stories of moving from and between sawmills and the ethnic economy highlight the fluidity of employment from the lumber industry to self-employment. This article thus argues for a remapping and expansion of existing visualizations of the Japanese community and for recognition of Japanese presence in the tideflats and sawmill spaces

From villains to victims: experiencing illness in Siberian exile

This essay presents the subjective experience of life and sickness for the punished in late Imperial Siberia, and the distinctions the punished made between legitimate and illegitimate forms of punishment. The essay also explores state policies towards the sick punished, and explores how different levels of the Tsarist administration and local Siberian society dealt with the challenge of sick and decrepit exiles. It argues that conditions in Siberian prisons were, in general, worse than those in European Russian prisons in the post-1906 period, and that the experience of exile in eastern Siberia placed it among the most difficult locations for exile. Though neither the state nor the punished regarded illness as an integral part of their punishment, the prevalence of illness and disease compounded the cruelty of sentences

A novel mechanism causing imbalance of mitochondrial fusion and fission in human myopathies.

Mitochondrial dynamics play an important role in cellular homeostasis and a variety of human diseases are linked to its dysregulated function. Here, we describe a 15-year-old boy with a novel disease caused by altered mitochondrial dynamics. The patient was the second child of consanguineous Jewish parents. He developed progressive muscle weakness and exercise intolerance at 6 years of age. His muscle biopsy revealed mitochondrial myopathy with numerous ragged red and cytochrome c oxidase (COX) negative fibers and combined respiratory chain complex I and IV deficiency. MtDNA copy number was elevated and no deletions of the mtDNA were detected in muscle DNA. Whole exome sequencing identified a homozygous nonsense mutation (p.Q92*) in the MIEF2 gene encoding the mitochondrial dynamics protein of 49 kDa (MID49). Immunoblotting revealed increased levels of proteins promoting mitochondrial fusion (MFN2, OPA1) and decreased levels of the fission protein DRP1. Fibroblasts of the patient showed elongated mitochondria, and significantly higher frequency of fusion events, mtDNA abundance and aberrant mitochondrial cristae ultrastructure, compared with controls. Thus, our data suggest that mutations in MIEF2 result in imbalanced mitochondrial dynamics and a combined respiratory chain enzyme defect in skeletal muscle, leading to mitochondrial myopathy

Kate 2006 Fall

Each year, kate seeks to: explore ideas about normative gender, sex, and sexuality work against oppression and hierarchies of power in any and all forms serve as a voice for race and gender equity as well as queer positivity encourage the silent to speak and feel less afraid build a zine and community that we care about and trusthttps://digitalcommons.otterbein.edu/kate/1004/thumbnail.jp

The beliefs about paranoia scale:Confirmatory factor analysis and tests of a metacognitive model of paranoia in a clinical sample

This study aimed to confirm the factor structure of the Beliefs about Paranoia Scale (BaPS), a self-report measure to assess metacognitive beliefs about paranoia, and to test hypotheses of a metacognitive model. We hypothesised that positive and negative beliefs about paranoia would be associated with severity of suspiciousness, and that the co-occurrence of positive and negative beliefs would be associated with increased suspiciousness. A total of 335 patients meeting criteria for a schizophrenia spectrum disorder completed the BaPS, the Positive and Negative Syndromes Scale (PANSS), and the Psychotic Symptom Rating Scales (PSYRATS). Confirmatory factor analysis verified that the three BaPS subscales (negative beliefs about paranoia, paranoia as a survival strategy, and normalizing beliefs) were an adequate fit of the data. Ordinal regression showed that positive beliefs about paranoia as a survival strategy and negative beliefs were both associated with severity of suspiciousness. This was the first study to show that the co-occurrence of positive and negative beliefs was associated with increased suspiciousness. All hypotheses were confirmed, suggesting that a metacognitive approach has utility for the conceptualization of paranoia. Clinical implications suggest a role for metacognitive therapy, including strategies such as detached mindfulness and worry postponement

Measuring common responses to psychosis:Assessing the psychometric properties of a new measure

Funding body agreements and policies The FOCUS Trial was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme (project number 10/101/02) and will be published in full in Health Technology Assessment. Visit the HTA programme website for further project information. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS or the Department of Health. Acknowledgements The authors would like to acknowledge The Psychosis Research Unit (PRU) Service User Reference Group (SURG) for their support with the FOCUS Trial and for their contribution to designing the Measure of Common Responses. We also acknowledge The Mental Health Research Network, Scottish Mental Health Research Network, FOCUS Trial Steering Committee and Data Monitoring and Ethics Committee. Thanks also to Lizi Graves, Susan Irving, Toyah Lebert, Liesbeth Tip, Maggie Douglas-Bailey and the other Research Assistants who have worked on the FOCUS Trial.Peer reviewedPostprin

Metabolic effects of bezafibrate in mitochondrial disease.

Funder: Medical Research Council (MRC): Confidence in Concept award to Newcastle UniversityMitochondrial disorders affect 1/5,000 and have no cure. Inducing mitochondrial biogenesis with bezafibrate improves mitochondrial function in animal models, but there are no comparable human studies. We performed an open-label observational experimental medicine study of six patients with mitochondrial myopathy caused by the m.3243A>G MTTL1 mutation. Our primary aim was to determine the effects of bezafibrate on mitochondrial metabolism, whilst providing preliminary evidence of safety and efficacy using biomarkers. The participants received 600-1,200 mg bezafibrate daily for 12 weeks. There were no clinically significant adverse events, and liver function was not affected. We detected a reduction in the number of complex IV-immunodeficient muscle fibres and improved cardiac function. However, this was accompanied by an increase in serum biomarkers of mitochondrial disease, including fibroblast growth factor 21 (FGF-21), growth and differentiation factor 15 (GDF-15), plus dysregulation of fatty acid and amino acid metabolism. Thus, although potentially beneficial in short term, inducing mitochondrial biogenesis with bezafibrate altered the metabolomic signature of mitochondrial disease, raising concerns about long-term sequelae

Cognitive behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT

Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people with schizophrenia who have a poor response to standard antipsychotic medication. However, a significant number of patients who trial clozapine have an inadequate response and experience persistent symptoms, called clozapine-resistant schizophrenia (CRS). There is little evidence regarding the clinical effectiveness of pharmacological or psychological interventions for this population. Objectives: To evaluate the clinical effectiveness and cost-effectiveness of cognitive–behavioural therapy (CBT) for people with CRS and to identify factors predicting outcome. Design: The Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial was a parallel-group, randomised, outcome-blinded evaluation trial. Randomisation was undertaken using permuted blocks of random size via a web-based platform. Data were analysed on an intention-to-treat (ITT) basis, using random-effects regression adjusted for site, age, sex and baseline symptoms. Cost-effectiveness analyses were carried out to determine whether or not CBT was associated with a greater number of quality-adjusted life-years (QALYs) and higher costs than treatment as usual (TAU). Setting: Secondary care mental health services in five cities in the UK. Participants: People with CRS aged up to 16 years, with an International Classification of Diseases, Tenth Revision (ICD-10) schizophrenia spectrum diagnoses and who are experiencing psychotic symptoms. Interventions: Individual CBT included up to 30 hours of therapy delivered over 9 months. The comparator was TAU, which included care co-ordination from secondary care mental health services. Main outcome measures: The primary outcome was the Positive and Negative Syndrome Scale (PANSS) total score at 21 months and the primary secondary outcome was PANSS total score at the end of treatment (9 months post randomisation). The health benefit measure for the economic evaluation was the QALY, estimated from the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), health status measure. Service use was measured to estimate costs. Results: Participants were allocated to CBT (n = 242) or TAU (n = 245). There was no significant difference between groups on the prespecified primary outcome [PANSS total score at 21 months was 0.89 points lower in the CBT arm than in the TAU arm, 95% confidence interval (CI) –3.32 to 1.55 points; p = 0.475], although PANSS total score at the end of treatment (9 months) was significantly lower in the CBT arm (–2.40 points, 95% CI –4.79 to –0.02 points; p = 0.049). CBT was associated with a net cost of £5378 (95% CI –£13,010 to £23,766) and a net QALY gain of 0.052 (95% CI 0.003 to 0.103 QALYs) compared with TAU. The cost-effectiveness acceptability analysis indicated a low likelihood that CBT was cost-effective, in the primary and sensitivity analyses (probability < 50%). In the CBT arm, 107 participants reported at least one adverse event (AE), whereas 104 participants in the TAU arm reported at least one AE (odds ratio 1.09, 95% CI 0.81 to 1.46; p = 0.58). Conclusions: Cognitive–behavioural therapy for CRS was not superior to TAU on the primary outcome of total PANSS symptoms at 21 months, but was superior on total PANSS symptoms at 9 months (end of treatment). CBT was not found to be cost-effective in comparison with TAU. There was no suggestion that the addition of CBT to TAU caused adverse effects. Future work could investigate whether or not specific therapeutic techniques of CBT have value for some CRS individuals, how to identify those who may benefit and how to ensure that effects on symptoms can be sustained. Trial registration: Current Controlled Trials ISRCTN99672552